Stocks · Health care · Medicinal Chemicals & Botanical Products

Definium Therapeutics, Inc.

DFTX Clue Score37
United States Fiscal year ends December CIK 0001813814 Results filed 6 Aug 2026

What the insiders did No buying or selling

By person

12 insiders · 0 transactions
123×

Robert Barrow holds 123 times base salary in stock. $80.93M of shares against $655.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Robert Barrow last reported holding, valued at $36.57, the price Common Shares was last bought or sold at on the open market here, on 25 Sep 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Robert Barrow
Chief Executive Officer
—
—
—
2,213,090
$80.93M
+880.6%
Daniel Karlin
Chief Medical Officer
—
—
—
792,846
$28.99M
+314.3%
Mark Sullivan
Chief Legal Officer
—
—
—
494,228
$18.07M
+848.1%
Brandi Roberts
Chief Financial Officer
—
—
—
394,528
$14.43M
+42,877%
Matthew T. Wiley
Chief Commercial Officer
—
—
—
359,036
$13.13M
—
Carrie Liao
Chief Accounting Officer
—
—
—
144,923
$5.30M
+45.6%
Roger Crystal
Director
—
—
—
24,289
$888.25K
+23.8%
Suzanne Louise Bruhn
Director
—
—
—
24,289
$888.25K
+23.8%
Carol A Vallone
Director
—
—
—
22,296
$815.36K
+34.8%
Andreas Krebs
Director
—
—
—
21,402
$782.67K
+41.7%
David W Gryska
Director
—
—
—
19,900
$727.74K
+56.3%
Roger Adsett
Director
—
—
—
3,555
$130.01K
—

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.